Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years

• Main Authors: Dan Bi (Author), Dan Apter (Author), Tiina Eriksson (Author), Mari Hokkanen (Author), Julia Zima (Author), Silvia Damaso (Author), Maaria Soila (Author), Gary Dubin (Author), Matti Lehtinen (Author), Frank Struyf (Author)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland (NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females only) using the AS04-adjuvanted human papillomavirus (HPV)-16/18 (AS04-HPV-16/18) vaccine....